Targeted therapies in pulmonary arterial hypertension

Pharmacology and Therapeutics

Volumn 141, Issue 2, 2014, Pages 172-191

  Montani, David ^a,b,c   Chaumais, Marie Camille ^a,c,d   Guignabert, Christophe ^a,b,c   Günther, Sven ^a,b,c   Girerd, Barbara ^a,b,c   Jaïs, Xavier ^a,b,c   Algalarrondo, Vincent ^a,d   Price, Laura C ^e   Savale, Laurent ^a,b,c   Sitbon, Olivier ^a,b,c   Simonneau, Gérald ^a,b,c   Humbert, Marc ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Endothelial dysfunction; Endothelin receptor antagonist; Kinase inhibitors; Prostacyclin; Pulmonary arterial hypertension; Type 5 phosphodiesterase inhibitors

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACITENTAN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RHO KINASE INHIBITOR; RIOCIGUAT; SELEXIPAG; VASOACTIVE INTESTINAL POLYPEPTIDE;

AUTOIMMUNITY; CARDIOTOXICITY; CELL METABOLISM; ENDOTHELIAL PROGENITOR CELL; GENETIC PREDISPOSITION; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; REVIEW; SIGNAL TRANSDUCTION;

ACTIVIN A RECEPTOR TYPE II-LIKE KINASE-1; ACVRL1; BMPR2; BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2; CALCIUM CHANNEL BLOCKERS; CAMP; CARDIAC OUTPUT; CCB; CGMP; CO; CYCLIC ADENOSINE MONOPHOSPHATE; CYCLIC GUANOSINE MONOPHOSPHATE; CYP; CYTOCHROME P450; EC; EGF; ENDOGLIN; ENDOTHELIAL CELL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ENG; EPIDERMAL GROWTH FACTOR; ERA; ET; FGF2; FIBROBLAST GROWTH FACTOR 2; IDIOPATHIC PAH; IPAH; IPR; KINASE INHIBITORS; KV; LEFT VENTRICULAR EJECTION FRACTION; LVEF; MCT; MEAN PULMONARY ARTERIAL PRESSURE; MONOCROTALINE; MPAP; NEW YORK HEART ASSOCIATION; NYHA; OS; OXIDATIVE STRESS; PAH; PASMC; PDE-5; PDGF; PGI2; PGI2 RECEPTOR; PH; PHOSPHODIESTERASE TYPE 5; PLATELET-DERIVED GROWTH FACTOR; PROSTACYCLIN; PULMONARY ARTERIAL HYPERTENSION; PULMONARY ARTERY SMOOTH MUSCLE CELLS; PULMONARY HYPERTENSION; PULMONARY VASCULAR RESISTANCE; PVR; REACTIVE OXYGEN SPECIES; RECEPTOR TYROSINE KINASE; RHOA/RHO KINASE; ROCK; ROS; RTK; SGC; SMC; SMOOTH MUSCLE CELL; SOD; SOLUBLE GUANYLATE CYCLASE; SUPEROXIDE DISMUTASE; TGF; THROMBOXANE; TKI; TRANSFORMING GROWTH FACTOR; TXA2; TYPE 5 PHOSPHODIESTERASE INHIBITORS; TYROSINE KINASE INHIBITOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VIP; VOLTAGE-GATED POTASSIUM CHANNELS; VPAC;

ANIMALS; HUMANS; HYPERTENSION, PULMONARY;

EID: 84891863007     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.10.002     Document Type: Review

References (321)

1. K. Abe, H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, and Y. Matsumoto et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats Circ Res 94 3 2004 385 393
2. K. Abe, S. Tawara, K. Oi, T. Hizume, T. Uwatoku, and Y. Fukumoto et al. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice J Cardiovasc Pharmacol 48 6 2006 280 285
3. Affsaps Thelin® (sitaxentan): retrait mondial du marché - Communiqué http://www.afssaps.fr/Infos-de-securite/Communiques-Points- presse/Thelin-R-sitaxentan-retrait-mondial-du-marche-Communique 2010 (Retrieved 09 January 2012)
4. G.S. Ahearn, M.A. Selim, and V.F. Tapson Severe erythroderma as a complication of continuous epoprostenol therapy Chest 122 1 2002 378 380
5. S.L. Archer, E. Chesler, J.N. Cohn, and E.K. Weir ZK 36-374, a stable analog of prostacyclin, prevents acute hypoxic pulmonary hypertension in the dog J Am Coll Cardiol 8 5 1986 1189 1194
6. T. Asaki, T. Hamamoto, Y. Sugiyama, K. Kuwano, and K. Kuwabara Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists Bioorg Med Chem 15 21 2007 6692 6704
7. E. Atallah, J.B. Durand, H. Kantarjian, and J. Cortes Congestive heart failure is a rare event in patients receiving imatinib therapy Blood 110 4 2007 1233 1237
8. C. Atkinson, S. Stewart, P.D. Upton, R. Machado, J.R. Thomson, and R.C. Trembath et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor Circulation 105 14 2002 1672 1678
9. E.D. Austin, L. Ma, C. LeDuc, E. Berman Rosenzweig, A. Borczuk, and J.A. Phillips 3rd et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension Circ Cardiovasc Genet 5 3 2012 336 343
10. D.B. Badesch, H.C. Champion, M.A. Sanchez, M.M. Hoeper, J.E. Loyd, and A. Manes et al. Diagnosis and assessment of pulmonary arterial hypertension J Am Coll Cardiol 54 1 Suppl. 2009 S55 S66
11. D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, L.J. Rubin, and F.M. Wigley et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Ann Intern Med 132 6 2000 425 434
12. K. Balabanian, A. Foussat, P. Dorfmuller, I. Durand-Gasselin, F. Capel, and L. Bouchet-Delbos et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension Am J Respir Crit Care Med 165 10 2002 1419 1425
13. A.C. Barreto, N.Y. Maeda, R.P. Soares, C. Cicero, and A.A. Lopes Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study Braz J Med Biol Res 41 8 2008 657 663
14. R.J. Barst, J.S. Gibbs, H.A. Ghofrani, M.M. Hoeper, V.V. McLaughlin, and L.J. Rubin et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 1 Suppl. 2009 S78 S84
15. R.J. Barst, M. McGoon, V. McLaughlin, V. Tapson, S. Rich, and L. Rubin et al. Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 41 12 2003 2119 2125
16. R.J. Barst, L.J. Rubin, W.A. Long, M.D. McGoon, S. Rich, and D.B. Badesch et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 5 1996 296 302
17. A. Bergeron, D. Rea, V. Levy, C. Picard, V. Meignin, and J. Tamburini et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series Am J Respir Crit Care Med 176 8 2007 814 818
18. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 6835 2001 355 365
19. M.H. Bolli, C. Boss, C. Binkert, S. Buchmann, D. Bur, and P. Hess The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4- pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist J Med Chem 55 17 2012 7849 7861
20. M. Bonnin, F.J. Mercier, O. Sitbon, S. Roger-Christoph, X. Jais, and M. Humbert et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases Anesthesiology 102 6 2005 1133 1137 (discussion 1135A-1136A)
21. R. Bowers, C. Cool, R.C. Murphy, R.M. Tuder, M.W. Hopken, and S.C. Flores et al. Oxidative stress in severe pulmonary hypertension Am J Respir Crit Care Med 169 6 2004 764 769
22. S. Bruderer, P. Aanismaa, M.C. Homery, S. Hausler, K. Landskroner, and P.N. Sidharta et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist AAPS J 14 1 2012 68 78
23. S. Bruderer, G. Hopfgartner, M. Seiberling, J. Wank, P.N. Sidharta, and A. Treiber et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans Xenobiotica 42 9 2012 901 910
24. G. Burgess, H. Hoogkamer, L. Collings, and J. Dingemanse Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil Eur J Clin Pharmacol 64 1 2008 43 50
25. M.C. Chaumais, M. Jobard, A. Huertas, C. Vignand-Courtin, M. Humbert, and O. Sitbon et al. Pharmacokinetic evaluation of continuous intravenous epoprostenol Expert Opin Drug Metab Toxicol 6 12 2010 1587 1598
26. S.J. Chen, Y.F. Chen, Q.C. Meng, J. Durand, V.S. Dicarlo, and S. Oparil Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats J Appl Physiol 79 6 1995 2122 2131
27. S.J. Chen, Y.F. Chen, T.J. Opgenorth, J.L. Wessale, Q.C. Meng, and J. Durand et al. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats J Cardiovasc Pharmacol 29 6 1997 713 725
28. K.M. Chin, R.N. Channick, J.A. de Lemos, N.H. Kim, F. Torres, and L.J. Rubin Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension Chest 135 1 2009 130 136
29. K.M. Chin, and L.J. Rubin Pulmonary arterial hypertension J Am Coll Cardiol 51 16 2008 1527 1538
30. B.W. Christman, C.D. McPherson, J.H. Newman, G.A. King, G.R. Bernard, and B.M. Groves et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N Engl J Med 327 2 1992 70 75
31. T.F. Chu, M.A. Rupnick, R. Kerkela, S.M. Dallabrida, D. Zurakowski, and L. Nguyen et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 9604 2007 2011 2019
32. L.H. Clapp, P. Finney, S. Turcato, S. Tran, L.J. Rubin, and A. Tinker Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery Am J Respir Cell Mol Biol 26 2 2002 194 201
33. M. Clozel, V. Breu, G.A. Gray, B. Kalina, B.M. Loffler, and K. Burri et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist J Pharmacol Exp Ther 270 1 1994 228 235
34. M. Clozel, and S. Roux The pharmacology of endothelin and its antagonist bosentan Ann Endocrinol (Paris) 61 1 2000 75 79
35. M.H. Cohen, G. Williams, J.R. Johnson, J. Duan, J. Gobburu, and A. Rahman et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia Clin Cancer Res 8 5 2002 935 942
36. R.A. Coleman, W.L. Smith, and S. Narumiya International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes Pharmacol Rev 46 2 1994 205 229
37. J.D. Corbin, A. Beasley, M.A. Blount, and S.H. Francis High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors Biochem Biophys Res Commun 334 3 2005 930 938
38. A. Courboulin, R. Paulin, N.J. Giguere, N. Saksouk, T. Perreault, and J. Meloche et al. Role for miR-204 in human pulmonary arterial hypertension J Exp Med 208 3 2011 535 548
39. A. Couvineau, and M. Laburthe VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins Br J Pharmacol 166 1 2012 42 50
40. J.L. Cracowski, B. Degano, F. Chabot, J. Labarere, E. Schwedhelm, and D. Monneret et al. Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension Chest 142 4 2012 869 876
41. J.L. Cracowski, C. Souvignet, N. Quirin, X. Grosbois, F. Bayle, and F. Stanke-Labesque et al. Urinary F2-isoprostanes formation in kidney transplantation Clin Transplant 15 1 2001 58 62
42. A. Csiszar, N. Labinskyy, S. Olson, J.T. Pinto, S. Gupte, and J.M. Wu et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats Hypertension 54 3 2009 668 675
43. G.E. D'Alonzo, R.J. Barst, S.M. Ayres, E.H. Bergofsky, B.H. Brundage, and K.M. Detre et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 5 1991 343 349
44. C.E. Daniels, J.A. Lasky, A.H. Limper, K. Mieras, E. Gabor, and D.R. Schroeder Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am J Respir Crit Care Med 181 6 2010 604 610
45. F.S. de Man, M.L. Handoko, H. Groepenhoff, A.J. van 't Hul, J. Abbink, and R.J. Koppers et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension Eur Respir J 34 3 2009 669 675
46. F.S. de Man, L. Tu, M.L. Handoko, S. Rain, G. Ruiter, and C. Francois et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension Am J Respir Crit Care Med 186 8 2012 780 789
47. Z. Deng, J.H. Morse, S.L. Slager, N. Cuervo, K.J. Moore, and G. Venetos et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene Am J Hum Genet 67 3 2000 737 744
48. J.S. Dhaliwal, A.M. Badejo Jr., D.B. Casey, S.N. Murthy, and P.J. Kadowitz Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl) -1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor J Pharmacol Exp Ther 330 1 2009 334 341
49. S. Dhillon, and G.M. Keating Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension Am J Cardiovasc Drugs 9 5 2009 331 350
50. G.P. Diller, S. van Eijl, D.O. Okonko, L.S. Howard, O. Ali, and T. Thum et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension Circulation 117 23 2008 3020 3030
51. Z. Do e, Y. Fukumoto, A. Takaki, S. Tawara, J. Ohashi, and M. Nakano et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension Circ J 73 9 2009 1731 1739
52. P. Dorfmuller, M.C. Chaumais, M. Giannakouli, I. Durand-Gasselin, N. Raymond, and E. Fadel et al. Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension Respir Res 12 2011 119
53. P. Dorfmuller, F. Perros, K. Balabanian, and M. Humbert Inflammation in pulmonary arterial hypertension Eur Respir J 22 2 2003 358 363
54. D. Dumitrescu, C. Seck, H. ten Freyhaus, F. Gerhardt, E. Erdmann, and S. Rosenkranz Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia Eur Respir J 38 1 2011 218 220
55. S. Duong-Quy, Y. Bei, Z. Liu, and A.T. Dinh-Xuan Role of Rho-kinase and its inhibitors in pulmonary hypertension Pharmacol Ther 137 3 2013
56. J. Dupuis, and M.M. Hoeper Endothelin receptor antagonists in pulmonary arterial hypertension Eur Respir J 31 2 2008 407 415
57. S. Eguchi, Y. Hirata, T. Imai, and F. Marumo Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculature Endocrinology 132 2 1993 524 529
58. M.M. Elgebaly, V. Portik-Dobos, K. Sachidanandam, D. Rychly, D. Malcom, and M.H. Johnson et al. Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes Vascul Pharmacol 47 2-3 2007 125 130
59. C.G. Elliott, E.W. Glissmeyer, G.T. Havlena, J. Carlquist, J.T. McKinney, and S. Rich et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension Circulation 113 21 2006 2509 2515
60. P. Escribano-Subias, I. Blanco, M. Lopez-Meseguer, C.J. Lopez-Guarch, A. Roman, and P. Morales et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry Eur Respir J 40 3 2012 596 603
61. O.V. Evgenov, P. Pacher, P.M. Schmidt, G. Hasko, H.H. Schmidt, and J.P. Stasch NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential Nat Rev Drug Discov 5 9 2006 755 768
62. K.A. Fagan, M. Oka, N.R. Bauer, S.A. Gebb, D.D. Ivy, and K.G. Morris et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase Am J Physiol Lung Cell Mol Physiol 287 4 2004 L656 L664
63. E. Falcetti, D.M. Flavell, B. Staels, A. Tinker, S.G. Haworth, and L.H. Clapp IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues Biochem Biophys Res Commun 360 4 2007 821 827
64. F. Farahmand, M.F. Hill, and P.K. Singal Antioxidant and oxidative stress changes in experimental cor pulmonale Mol Cell Biochem 260 1-2 2004 21 29
65. K. Fattinger, C. Funk, M. Pantze, C. Weber, J. Reichen, and B. Stieger et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions Clin Pharmacol Ther 69 4 2001 223 231
66. R. Ferrari, A. Cargnoni, S. Curello, G.M. Boffa, and C. Ceconi Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts Br J Pharmacol 98 2 1989 678 684
67. J.G. Filep, A. Fournier, and E. Foldes-Filep Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors Br J Pharmacol 115 2 1995 227 236
68. A.S. Forrest, G.W. Hennig, S. Jokela-Willis, C.D. Park, and K.M. Sanders Prostaglandin regulation of gastric slow waves and peristalsis Am J Physiol Gastrointest Liver Physiol 296 6 2009 G1180 G1190
69. I. Frachon, S.P. Gaudin, C. Jezequel, X. Jais, C. Gut-Gobert, and S.R. Christophe et al. Contraception, therapeutic abortion, and pulmonary arterial hypertension Presse Med 39 Suppl. 1 2010 (1S46-50)
70. J.E. Frampton Ambrisentan Am J Cardiovasc Drugs 11 4 2011 215 226
71. H. Frank, J. Mlczoch, K. Huber, E. Schuster, H.P. Gurtner, and M. Kneussl The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension Chest 112 3 1997 714 721
72. R. Frey, W. Muck, S. Unger, U. Artmeier-Brandt, G. Weimann, and G. Wensing Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers J Clin Pharmacol 48 8 2008 926 934
73. A. Friebe, and D. Koesling Regulation of nitric oxide-sensitive guanylyl cyclase Circ Res 93 2 2003 96 105
74. R. Friedman, J.G. Mears, and R.J. Barst Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension Circulation 96 9 1997 2782 2784
75. H. Fujita, Y. Fukumoto, K. Saji, K. Sugimura, J. Demachi, and J. Nawata et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension Heart Vessels 25 2 2010 144 149
76. Y. Fukumoto, T. Matoba, A. Ito, H. Tanaka, T. Kishi, and S. Hayashidani et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension Heart 91 3 2005 391 392
77. V. Fuster, P.M. Steele, W.D. Edwards, B.J. Gersh, M.D. McGoon, and R.L. Frye Primary pulmonary hypertension: natural history and the importance of thrombosis Circulation 70 4 1984 580 587
78. N. Galiè Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH) Am J Respir Crit Care Med 181 2010 B116
79. N. Galie, B.H. Brundage, H.A. Ghofrani, R.J. Oudiz, G. Simonneau, and Z. Safdar et al. Tadalafil therapy for pulmonary arterial hypertension Circulation 119 22 2009 2894 2903
80. N. Galie, H.A. Ghofrani, A. Torbicki, R.J. Barst, L.J. Rubin, and D. Badesch et al. Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 20 2005 2148 2157
81. N. Galie, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, and J.A. Barbera et al. Guidelines for the diagnosis and treatment of pulmonary hypertension Eur Respir J 34 6 2009 1219 1263
82. N. Galie, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, and J.A. Barbera et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 20 2009 2493 2537
83. N. Galie, M. Humbert, J.L. Vachiery, C.D. Vizza, M. Kneussl, and A. Manes et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 39 9 2002 1496 1502
84. N. Galie, A. Manes, and A. Branzi The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Eur Respir J 20 4 2002 1037 1049
85. N. Galie, H. Olschewski, R.J. Oudiz, F. Torres, A. Frost, and H.A. Ghofrani et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 23 2008 3010 3019
86. N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, and T. Higenbottam et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur Heart J 25 24 2004 2243 2278
87. M.W. Geraci, M. Moore, T. Gesell, M.E. Yeager, L. Alger, and H. Golpon et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis Circ Res 88 6 2001 555 562
88. S. Ghio, D. Bonderman, S.B. Felix, H.A. Ghofrani, E.D. Michelakis, and V. Mitrovic et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design Eur J Heart Fail 14 8 2012 946 953
89. H. Ghofrani, N. Galie, F. Grimminger, M. Humbert, A. Keogh, and D. Langleben et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study (PATENT-1) Chest 142 2012 1027A 10.1378/chest.1462799 (No. 4 MeetingAbstracts)
90. H.A. Ghofrani, and F. Grimminger Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Eur Respir Rev 18 111 2009 35 41
91. H.A. Ghofrani, M.M. Hoeper, M. Halank, F.J. Meyer, G. Staehler, and J. Behr et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Eur Respir J 36 4 2010 792 799
92. H.A. Ghofrani, N.W. Morrell, M.M. Hoeper, H. Olschewski, A.J. Peacock, and R.J. Barst et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy Am J Respir Crit Care Med 182 9 2010 1171 1177
93. H.A. Ghofrani, W. Seeger, and F. Grimminger Imatinib for the treatment of pulmonary arterial hypertension N Engl J Med 353 13 2005 1412 1413
94. H.A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Olschewski, P. Haredza, and B. Karadas et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study J Am Coll Cardiol 44 7 2004 1488 1496
95. A. Giaid, M. Yanagisawa, D. Langleben, R.P. Michel, R. Levy, and H. Shennib et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 24 1993 1732 1739
96. D. Giordano, M.E. De Stefano, G. Citro, A. Modica, and M. Giorgi Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain Biochim Biophys Acta 1539 1-2 2001 16 27
97. B. Girerd, D. Montani, F. Coulet, B. Sztrymf, A. Yaici, and X. Jais et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation Am J Respir Crit Care Med 181 8 2010 851 861
98. R.E. Girgis, D. Li, X. Zhan, J.G. Garcia, R.M. Tuder, and P.M. Hassoun et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin Am J Physiol Heart Circ Physiol 285 3 2003 H938 H945
99. R.E. Girgis, S. Mozammel, H.C. Champion, D. Li, X. Peng, and L. Shimoda et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin Am J Physiol Lung Cell Mol Physiol 292 5 2007 L1105 L1110
100. M. Gomberg-Maitland, M.L. Maitland, R.J. Barst, L. Sugeng, S. Coslet, and T.J. Perrino et al. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension Clin Pharmacol Ther 87 3 2010 303 310
101. M. Gomberg-Maitland, V.F. Tapson, R.L. Benza, V.V. McLaughlin, A. Krichman, and A.C. Widlitz et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension Am J Respir Crit Care Med 172 12 2005 1586 1589
102. B. Gregan, J. Jurgensen, G. Papsdorf, J. Furkert, M. Schaefer, and M. Beyermann et al. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers J Biol Chem 279 26 2004 27679 27687
103. F. Grimminger, G. Weimann, R. Frey, R. Voswinckel, M. Thamm, and D. Bolkow et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Eur Respir J 33 4 2009 785 792
104. E. Grunig, M. Lichtblau, N. Ehlken, H.A. Ghofrani, F. Reichenberger, and G. Staehler et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension Eur Respir J 40 1 2012 84 92
105. E. Grunig, S. Weissmann, N. Ehlken, A. Fijalkowska, C. Fischer, and T. Fourme et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia Circulation 119 13 2009 1747 1757
106. R.J. Gryglewski, S. Bunting, S. Moncada, R.J. Flower, and J.R. Vane Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides Prostaglandins 12 5 1976 685 713
107. C. Guignabert, L. Tu, M. Izikki, L. Dewachter, P. Zadigue, and M. Humbert et al. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter FASEB J 23 12 2009 4135 4147
108. C. Guilluy, S. Eddahibi, C. Agard, C. Guignabert, M. Izikki, and L. Tu et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling Am J Respir Crit Care Med 179 12 2009 1151 1158
109. C. Guilluy, V. Sauzeau, M. Rolli-Derkinderen, P. Guerin, C. Sagan, and P. Pacaud et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension Br J Pharmacol 146 7 2005 1010 1018
110. C.L. Guimaraes, S. Da-Silva, R. Couture, and G.A. Rae Mixed endothelin ET(A) and ET(B) antagonist bosentan inhibits oleic acid-induced lung plasma extravasation in mouse J Cardiovasc Pharmacol 36 5 Suppl. 1 2000 S371 S373
111. S. Gur, S.C. Sikka, and W.J. Hellstrom Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress Expert Opin Investig Drugs 17 6 2008 855 864
112. S.A. Hamidi, R.Z. Lin, A.M. Szema, S. Lyubsky, Y.P. Jiang, and S.I. Said VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension Respir Res 12 2011 141
113. H. Hashimoto, M. Negishi, and A. Ichikawa Identification of a prostacyclin receptor coupled to the adenylate cyclase system via a stimulatory GTP-binding protein in mouse mastocytoma P-815 cells Prostaglandins 40 5 1990 491 505
114. I.R. Henkens, T. Hazenoot, A. Boonstra, M.V. Huisman, and A. Vonk-Noordegraaf Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension Eur Respir J 41 4 2012 872 878
115. T.W. Higenbottam, A.Y. Butt, A.T. Dinh-Xaun, M. Takao, G. Cremona, and S. Akamine Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost Heart 79 2 1998 175 179
116. M.M. Hoeper Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy? Eur Respir J 34 3 2009 529 530
117. M. Hoeper, R. Barst, H.J. Chang, R.P. Frantz, Y. Fukumoto, and N. Galié et al. Imatinib safety and efficacy: interim analysis of IMPRES extension study in patients with pulmonary arterial hypertension Am J Respir Crit Care Med 185 2012 A2495
118. M.M. Hoeper, C. Faulenbach, H. Golpon, J. Winkler, T. Welte, and J. Niedermeyer Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Eur Respir J 24 6 2004 1007 1010
119. M.M. Hoeper, H. Gall, H.J. Seyfarth, M. Halank, H.A. Ghofrani, and J. Winkler et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Eur Respir J 34 1 2009 132 137
120. M.M. Hoeper, M. Halank, H. Wilkens, A. Gunther, G. Weimann, and I. Gebert et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial Eur Respir J 41 4 2013 853 860
121. M.M. Hoeper, M. Schwarze, S. Ehlerding, A. Adler-Schuermeyer, E. Spiekerkoetter, and J. Niedermeyer et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue N Engl J Med 342 25 2000 1866 1870
122. Y. Hoshikawa, S. Ono, S. Suzuki, T. Tanita, M. Chida, and C. Song et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia J Appl Physiol 90 4 2001 1299 1306
123. A. Huertas, L. Tu, N. Gambaryan, B. Girerd, F. Perros, and D. Montani et al. Leptin and regulatory T lymphocytes in idiopathic pulmonary arterial hypertension Eur Respir J 40 4 2012 895 904
124. M. Humbert, R.J. Barst, I.M. Robbins, R.N. Channick, N. Galie, and A. Boonstra et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 24 3 2004 353 359
125. M. Humbert, Z. Deng, G. Simonneau, R.J. Barst, O. Sitbon, and M. Wolf et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives Eur Respir J 20 3 2002 518 523
126. M. Humbert, G. Monti, F. Brenot, O. Sitbon, A. Portier, and L. Grangeot-Keros et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension Am J Respir Crit Care Med 151 5 1995 1628 1631
127. M. Humbert, G. Monti, M. Fartoukh, A. Magnan, F. Brenot, and B. Rain et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients Eur Respir J 11 3 1998 554 559
128. M. Humbert, E.S. Segal, D.G. Kiely, J. Carlsen, B. Schwierin, and M.M. Hoeper Results of European post-marketing surveillance of bosentan in pulmonary hypertension Eur Respir J 30 2 2007 338 344
129. M. Humbert, O. Sitbon, A. Chaouat, M. Bertocchi, G. Habib, and V. Gressin et al. Survival in patients with idiopathic, familial, and anorexigen- associated pulmonary arterial hypertension in the modern management era Circulation 122 2 2010 156 163
130. M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension N Engl J Med 351 14 2004 1425 1436
131. M. Humbert, O. Sitbon, A. Yaici, D. Montani, D.S. O'Callaghan, and X. Jais et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension Eur Respir J 36 3 2010 549 555
132. M. Iglarz, C. Binkert, K. Morrison, W. Fischli, J. Gatfield, and A. Treiber et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist J Pharmacol Exp Ther 327 3 2008 736 745
133. Y. Ikeda, Y. Yonemitsu, C. Kataoka, S. Kitamoto, T. Yamaoka, and K. Nishida et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats Am J Physiol Heart Circ Physiol 283 5 2002 H2021 H2028
134. M. Izikki, C. Guignabert, E. Fadel, M. Humbert, L. Tu, and P. Zadigue et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents J Clin Invest 119 3 2009 512 523
135. Z. Jaffar, M.E. Ferrini, M.C. Buford, G.A. Fitzgerald, and K. Roberts Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma J Immunol 179 9 2007 6193 6203
136. X. Jais, K.M. Olsson, J.A. Barbera, I. Blanco, A. Torbicki, and A. Peacock et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era Eur Respir J 40 4 2012 881 885
137. M. Jerkic, M.G. Kabir, A. Davies, L.X. Yu, B.A. McIntyre, and N.W. Husain et al. Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress Cardiovasc Res 92 3 2011 375 384
138. Z.C. Jing, X. Jiang, B.X. Wu, X.Q. Xu, Y. Wu, and C.R. Ma et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study Heart 95 18 2009 1531 1536
139. A.J. Kallen, E. Lederman, A. Balaji, I. Trevino, E.E. Petersen, and R. Shoulson et al. Bloodstream infections in patients given treatment with intravenous prostanoids Infect Control Hosp Epidemiol 29 4 2008 342 349
140. F. Kamezaki, H. Tasaki, K. Yamashita, M. Tsutsui, S. Koide, and S. Nakata et al. Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats Am J Respir Crit Care Med 177 2 2008 219 226
141. K.K. Kan, R.L. Jones, M.P. Ngan, and J.A. Rudd Actions of prostanoids to induce emesis and defecation in the ferret Eur J Pharmacol 453 2-3 2002 299 308
142. H. Kantarjian, N.P. Shah, A. Hochhaus, J. Cortes, S. Shah, and M. Ayala et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 24 2010 2260 2270
143. P.N. Kao Simvastatin treatment of pulmonary hypertension: an observational case series Chest 127 4 2005 1446 1452
144. G.K. Karavolias, P. Georgiadou, A. Gkouziouta, P. Kariofillis, G. Karabela, and D. Tsiapras et al. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses Expert Opin Ther Targets 14 12 2010 1283 1289
145. N. Katsiki, A.S. Wierzbicki, and D.P. Mikhailidis Pulmonary arterial hypertension and statins: an update Curr Opin Cardiol 26 4 2011 322 326
146. S.M. Kawut, E. Bagiella, D.J. Lederer, D. Shimbo, E.M. Horn, and K.E. Roberts et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT Circulation 123 25 2011 2985 2993
147. K. Kemp, L. Savale, D.S. O'Callaghan, X. Jais, D. Montani, and M. Humbert et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study J Heart Lung Transplant 31 2 2012 150 158
148. R. Kerkela, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, and C. Beahm et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 8 2006 908 916
149. H. Kim, G.L. Yung, J.J. Marsh, R.G. Konopka, C.A. Pedersen, and P.G. Chiles et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension Eur Respir J 15 4 2000 640 648
150. M. Klein, R.T. Schermuly, P. Ellinghaus, H. Milting, B. Riedl, and S. Nikolova et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling Circulation 118 20 2008 2081 2090
151. B. Kojonazarov, A. Myrzaakhmatova, T. Sooronbaev, T. Ishizaki, and A. Aldashev Effects of fasudil in patients with high-altitude pulmonary hypertension Eur Respir J 39 2 2012 496 498
152. W. Krause, and T. Krais Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man Eur J Clin Pharmacol 30 1 1986 61 68
153. U. Krishnan, S. Takatsuki, D.D. Ivy, J. Kerstei, M. Calderbank, and E. Coleman Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children Am J Cardiol 110 11 2012 1704 1709
154. O. Kummer, M. Haschke, F. Hammann, M. Bodmer, S. Bruderer, and Y. Regnault et al. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan Eur J Pharm Sci 38 4 2009 384 388
155. K. Kuwano, A. Hashino, T. Asaki, T. Hamamoto, T. Yamada, and K. Okubo et al. 2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug J Pharmacol Exp Ther 322 3 2007 1181 1188
156. K. Kuwano, A. Hashino, K. Noda, K. Kosugi, and K. Kuwabara A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6- diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery J Pharmacol Exp Ther 326 3 2008 691 699
157. K. Laliberte, C. Arneson, R. Jeffs, T. Hunt, and M. Wade Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers J Cardiovasc Pharmacol 44 2 2004 209 214
158. O. Lambert, D. Bandilla, R. Iyer, L. Witchey-Lakshmanan, and N. Palepu Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted Drug Des Devel Ther 6 2012 61 70
159. K.B. Lane, R.D. Machado, M.W. Pauciulo, J.R. Thomson, J.A. Phillips III, and J.E. Loyd et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension Nat Genet 26 1 2000 81 84
160. K.L. Lane, M. Talati, E. Austin, A.R. Hemnes, J.A. Johnson, and J.P. Fessel et al. Oxidative injury is a common consequence of BMPR2 mutations Pulm Circ 1 1 2011 72 83
161. M. Lang, B. Kojonazarov, X. Tian, A. Kalymbetov, N. Weissmann, and F. Grimminger et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats PLoS One 7 8 2012 e43433
162. A. Lavelle, R. Sugrue, G. Lawler, N. Mulligan, B. Kelleher, and D.M. Murphy et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension Eur Respir J 34 3 2009 770 771
163. T.M. Lee, C.C. Chen, H.N. Shen, and N.C. Chang Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension Clin Sci (Lond) 116 6 2009 497 505
164. W.T. Lee, N. Kirkham, M.K. Johnson, J.L. Lordan, A.J. Fisher, and A.J. Peacock Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension Eur Respir J 37 2 2011 472 474
165. W.T. Lee, Y. Ling, K.K. Sheares, J. Pepke-Zaba, A.J. Peacock, and M.K. Johnson Predicting survival in pulmonary arterial hypertension in the UK Eur Respir J 40 3 2012 604 611
166. C.W. Leffler, and J.R. Hessler Pulmonary and systemic vascular effects of exogenous prostaglandin I2 in fetal lambs Eur J Pharmacol 54 1-2 1979 37 42
167. H.H. Leuchte, C. Baezner, R.A. Baumgartner, D. Bevec, G. Bacher, and C. Neurohr et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension Eur Respir J 32 5 2008 1289 1294
168. S. Li, S.S. Tabar, V. Malec, B.G. Eul, W. Klepetko, and N. Weissmann et al. NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts Antioxid Redox Signal 10 10 2008 1687 1698
169. F. Li, W. Xia, A. Li, C. Zhao, and R. Sun Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats Pharmacol Res 55 1 2007 64 71
170. H. Lim, and S.K. Dey A novel pathway of prostacyclin signaling - hanging out with nuclear receptors Endocrinology 143 9 2002 3207 3210
171. T.M. Lincoln, N.B. Dey, N.J. Boerth, T.L. Cornwell, and G.A. Soff Nitric oxide - cyclic GMP pathway regulates vascular smooth muscle cell phenotypic modulation: implications in vascular diseases Acta Physiol Scand 164 4 1998 507 515
172. Y. Ling, M.K. Johnson, D.G. Kiely, R. Condliffe, C.A. Elliot, and J.S. Gibbs et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland Am J Respir Crit Care Med 186 8 2012 790 796
173. A.J. Liu, F. Ling, D. Wang, Q. Wang, X.D. Lu, and Y.L. Liu Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip(1) via the ERK signal pathway Chin Med J (Engl) 124 19 2011 3098 3104
174. L.J. Lombardo, F.Y. Lee, P. Chen, D. Norris, J.C. Barrish, and K. Behnia et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 27 2004 6658 6661
175. L. Ma, D. Roman-Campos, E.D. Austin, M. Eyries, K.S. Sampson, and F. Soubrier et al. A novel channelopathy in pulmonary arterial hypertension N Engl J Med 369 4 2013 351 361
176. B. Magnani, and N. Galie Prostacyclin in primary pulmonary hypertension Eur Heart J 17 1 1996 18 24
177. S.A. Maher, and M.G. Belvisi Prostanoids and cough reflex Lung 188 Suppl 1 2010 S9 S12
178. B.A. Markewitz, I.S. Farrukh, Y. Chen, Y. Li, and J.R. Michael Regulation of endothelin-1 synthesis in human pulmonary arterial smooth muscle cells. Effects of transforming growth factor-beta and hypoxia Cardiovasc Res 49 1 2001 200 206
179. K. Maruno, A. Absood, and S.I. Said VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells Am J Physiol 268 6 Pt 1 1995 L1047 L1051
180. D. Masiello, G. Gorospe III, and A.S. Yang The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib J Hematol Oncol 2 2009 46
181. R. Mathew, N. Yuan, L. Rosenfeld, M.H. Gewitz, and A. Kumar Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs Heart Dis 4 3 2002 152 158
182. M. Max, R. Kuhlen, R. Dembinski, and R. Rossaint Effect of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension Intensive Care Med 25 10 1999 1147 1154
183. B. Mayer, and B. Hemmens Biosynthesis and action of nitric oxide in mammalian cells Trends Biochem Sci 22 12 1997 477 481
184. M.D. McGoon, A.E. Frost, R.J. Oudiz, D.B. Badesch, N. Galie, and H. Olschewski et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities Chest 135 1 2009 122 129
185. V.V. McLaughlin, R.L. Benza, L.J. Rubin, R.N. Channick, R. Voswinckel, and V.F. Tapson et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial J Am Coll Cardiol 55 18 2010 1915 1922
186. V.V. McLaughlin, S.P. Gaine, R.J. Barst, R.J. Oudiz, R.C. Bourge, and A. Frost et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension J Cardiovasc Pharmacol 41 2 2003 293 299
187. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 12 2002 1477 1482
188. M.S. McMurtry, S. Bonnet, X. Wu, J.R. Dyck, A. Haromy, and K. Hashimoto et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis Circ Res 95 8 2004 830 840
189. S.L. Merklinger, P.L. Jones, E.C. Martinez, and M. Rabinovitch Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension Circulation 112 3 2005 423 431
190. E.D. Michelakis, M.S. McMurtry, X.C. Wu, J.R. Dyck, R. Moudgil, and T.A. Hopkins et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels Circulation 105 2 2002 244 250
191. E. Michelakis, W. Tymchak, D. Lien, L. Webster, K. Hashimoto, and S. Archer Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide Circulation 105 20 2002 2398 2403
192. C. Midgett, J. Stitham, K.A. Martin, and J. Hwa Prostacyclin receptor regulation - from transcription to trafficking Curr Mol Med 11 7 2011 517 528
193. D.P. Miller, M. Gomberg-Maitland, and M. Humbert Survivor bias and risk assessment Eur Respir J 40 3 2012 530 532
194. T. Minami, H. Nakano, T. Kobayashi, Y. Sugimoto, F. Ushikubi, and A. Ichikawa et al. Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice Br J Pharmacol 133 3 2001 438 444
195. M. Mittal, M. Roth, P. Konig, S. Hofmann, E. Dony, and P. Goyal et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature Circ Res 101 3 2007 258 267
196. J. Mittendorf, S. Weigand, C. Alonso-Alija, E. Bischoff, A. Feurer, and M. Gerisch et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension ChemMedChem 4 5 2009 853 865
197. M. Miyata, Y. Ueno, H. Sekine, O. Ito, F. Sakuma, and H. Koike et al. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension J Cardiovasc Pharmacol 27 1 1996 20 26
198. S. Moncada, and A. Higgs The L-arginine-nitric oxide pathway N Engl J Med 329 27 1993 2002 2012
199. D. Montani, L. Achouh, A.G. Marcelin, J.P. Viard, O. Hermine, and D. Canioni et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease Eur Respir J 26 5 2005 969 972
200. D. Montani, E. Bergot, S. Gunther, L. Savale, A. Bergeron, and A. Bourdin et al. Pulmonary arterial hypertension in patients treated by dasatinib Circulation 125 17 2012 2128 2137
201. D. Montani, M.C. Chaumais, L. Savale, D. Natali, L.C. Price, and X. Jais et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension Adv Ther 26 9 2009 813 825
202. D. Montani, L. Savale, D. Natali, X. Jais, P. Herve, and G. Garcia et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension Eur Heart J 31 15 2010 1898 1907
203. L. Moreno-Vinasco, M. Gomberg-Maitland, M.L. Maitland, A.A. Desai, P.A. Singleton, and S. Sammani et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension Physiol Genomics 33 2 2008 278 291
204. K. Morrison, R. Ernst, P. Hess, R. Studer, and M. Clozel Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function J Pharmacol Exp Ther 335 1 2010 249 255
205. K. Morrison, R. Studer, R. Ernst, F. Haag, K. Kauser, and M. Clozel Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery J Pharmacol Exp Ther 343 3 2012 547 555
206. K.T. Mouchaers, I. Schalij, M.A. de Boer, P.E. Postmus, V.W. van Hinsbergh, and G.P. van Nieuw Amerongen et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil Eur Respir J 36 4 2010 800 807
207. K.K. Mubarak A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension Respir Med 104 1 2010 9 21
208. T. Nagaoka, K.A. Fagan, S.A. Gebb, K.G. Morris, T. Suzuki, and H. Shimokawa et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension Am J Respir Crit Care Med 171 5 2005 494 499
209. C. Nagaraj, B. Tang, Z. Balint, M. Wygrecka, A. Hrzenjak, and G. Kwapiszewska et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries Eur Respir J 41 1 2012 85 95
210. H. Nagumo, Y. Sasaki, Y. Ono, H. Okamoto, M. Seto, and Y. Takuwa Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells Am J Physiol Cell Physiol 278 1 2000 C57 C65
211. P.A. Nandiwada, P.J. Kadowitz, S.I. Said, M. Mojarad, and A.L. Hyman Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat J Appl Physiol 58 5 1985 1723 1728
212. M.T. Nasim, T. Ogo, M. Ahmed, R. Radall, H.M. Chowdhury, and K.M. Snape et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension Hum Mutat 32 12 2011 1385 1389
213. NIH ClinicalTrials.gov. ACT-293987 in Pulmonary Arterial Hypertension [Online] 2011
214. T. Nishimura, J.L. Faul, G.J. Berry, L.T. Vaszar, D. Qiu, and R.G. Pearl et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats Am J Respir Crit Care Med 166 10 2002 1403 1408
215. T. Nishimura, L.T. Vaszar, J.L. Faul, G. Zhao, G.J. Berry, and L. Shi et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells Circulation 108 13 2003 1640 1645
216. Y. Oda, B. Renaux, J. Bjorge, M. Saifeddine, D.J. Fujita, and M.D. Hollenberg cSrc is a major cytosolic tyrosine kinase in vascular tissue Can J Physiol Pharmacol 77 8 1999 606 617
217. H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, and L.J. Rubin et al. Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 5 2002 322 329
218. C.F. Opitz, R. Wensel, M. Bettmann, R. Schaffarczyk, M. Linscheid, and R. Hetzer et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation Eur Heart J 24 4 2003 356 365
219. R.J. Oudiz Pulmonary hypertension associated with left-sided heart disease Clin Chest Med 28 1 2007 233 241
220. R.J. Oudiz, and H.W. Farber Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review Am Heart J 157 4 2009 625 635
221. M. Packer, N. Medina, M. Yushak, and I. Wiener Detrimental effects of verapamil in patients with primary pulmonary hypertension Br Heart J 52 1 1984 106 111
222. A. Pal, J.G. Brasseur, and B. Abrahamsson A stomach road or "Magenstrasse" for gastric emptying J Biomech 40 6 2007 1202 1210
223. E.A. Pankey, R.J. Byun, W.B. Smith II, M. Bhartiya, F.R. Bueno, and A.M. Badejo et al. The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat Can J Physiol Pharmacol 90 7 2012 825 835
224. F. Perros, P. Dorfmuller, D. Montani, H. Hammad, W. Waelput, and B. Girerd et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med 185 3 2012 311 321
225. F. Perros, D. Montani, P. Dorfmuller, I. Durand-Gasselin, C. Tcherakian, and J. Le Pavec et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med 178 1 2008 81 88
226. F. Perros, D. Montani, P. Dorfmuller, A. Huertas, M.C. Chaumais, and S. Cohen-Kaminsky et al. Novel immunopathological approaches to pulmonary arterial hypertension Presse Med 40 Suppl. 1 2011 1S3-13
227. V. Petkov, W. Mosgoeller, R. Ziesche, M. Raderer, L. Stiebellehner, and K. Vonbank et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension J Clin Invest 111 9 2003 1339 1346
228. L.C. Price, D. Montani, C. Tcherakian, P. Dorfmuller, R. Souza, and N. Gambaryan et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Eur Respir J 37 4 2011 813 822
229. T. Pulido, I. Adzerikho, R.N. Channick, M. Delcroix, N. Galie, and H.A. Ghofrani et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH) N Engl J Med 369 2013 809 818
230. A. Quintas-Cardama, H. Kantarjian, S. O'Brien, G. Borthakur, J. Bruzzi, and R. Munden et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure J Clin Oncol 25 25 2007 3908 3914
231. K.F. Rabe, H. Tenor, G. Dent, C. Schudt, M. Nakashima, and H. Magnussen Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors Am J Physiol 266 5 Pt 1 1994 L536 L543
232. B. Raychaudhuri, A. Malur, T.L. Bonfield, S. Abraham, R.J. Schilz, and C.F. Farver et al. The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages J Biol Chem 277 36 2002 33344 33348
233. E.M. Redout, A. van der Toorn, M.J. Zuidwijk, C.W. van de Kolk, C.J. van Echteld, and R.J. Musters et al. Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure Am J Physiol Heart Circ Physiol 298 3 2010 H1038 H1047
234. E.M. Redout, M.J. Wagner, M.J. Zuidwijk, C. Boer, R.J. Musters, and C. van Hardeveld et al. Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species Cardiovasc Res 75 4 2007 770 781
235. J. Rehman, and S.L. Archer A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension Adv Exp Med Biol 661 2010 171 185
236. K.A. Reisbig, P.A. Coffman, A.A. Floreani, C.J. Bultsma, and K.M. Olsen Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension Ann Pharmacother 39 4 2005 739 743
237. A.M. Reynolds, M.D. Holmes, S.M. Danilov, and P.N. Reynolds Targeted gene delivery of BMPR2 attenuates pulmonary hypertension Eur Respir J 39 2 2012 329 343
238. C.J. Rhodes, A. Davidson, J.S. Gibbs, J. Wharton, and M.R. Wilkins Therapeutic targets in pulmonary arterial hypertension Pharmacol Ther 121 1 2009 69 88
239. S. Rich, E. Kaufmann, and P.S. Levy The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N Engl J Med 327 2 1992 76 81
240. E.B. Rosenzweig, J.H. Morse, J.A. Knowles, K.K. Chada, A.M. Khan, and K.E. Roberts et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension J Heart Lung Transplant 27 6 2008 668 674
241. N. Roubinian, C.G. Elliott, C.F. Barnett, P.D. Blanc, J. Chen, and T. De Marco et al. Effects of commercial air travel on patients with pulmonary hypertension air travel and pulmonary hypertension Chest 142 4 2012 885 892
242. L.J. Rubin Primary pulmonary hypertension N Engl J Med 336 2 1997 111 117
243. L.J. Rubin Exercise training for pulmonary hypertension: another prescription to write? Eur Respir J 40 1 2012 7 8
244. L.J. Rubin, D.B. Badesch, R.J. Barst, N. Galie, C.M. Black, and A. Keogh et al. Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 12 2002 896 903
245. L.J. Rubin, J. Mendoza, M. Hood, M. McGoon, R. Barst, and W.B. Williams et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial Ann Intern Med 112 7 1990 485 491
246. S.D. Rybalkin, C. Yan, K.E. Bornfeldt, and J.A. Beavo Cyclic GMP phosphodiesterases and regulation of smooth muscle function Circ Res 93 4 2003 280 291
247. R. Sadushi-Kolici, N. Skoro-Sajer, D. Zimmer, D. Bonderman, M. Schemper, and W. Klepetko et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension J Heart Lung Transplant 31 7 2012 735 743
248. T. Saga, and S.I. Said Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma Trans Assoc Am Physicians 97 1984 304 310
249. S.I. Said The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation Ann N Y Acad Sci 1144 2008 148 153
250. S.I. Said, S.A. Hamidi, K.G. Dickman, A.M. Szema, S. Lyubsky, and R.Z. Lin et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene Circulation 115 10 2007 1260 1268
251. O. Sanchez, E. Marcos, F. Perros, E. Fadel, L. Tu, and M. Humbert et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med 176 10 2007 1041 1047
252. O. Sanchez, O. Sitbon, X. Jais, G. Simonneau, and M. Humbert Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension Chest 130 1 2006 182 189
253. R. Sarkar, E.G. Meinberg, J.C. Stanley, D. Gordon, and R.C. Webb Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells Circ Res 78 2 1996 225 230
254. R.T. Schermuly, E. Dony, H.A. Ghofrani, S. Pullamsetti, R. Savai, and M. Roth et al. Reversal of experimental pulmonary hypertension by PDGF inhibition J Clin Invest 115 10 2005 2811 2821
255. R.T. Schermuly, W. Janssen, N. Weissmann, J.P. Stasch, F. Grimminger, and H.A. Ghofrani Riociguat for the treatment of pulmonary hypertension Expert Opin Investig Drugs 20 4 2011 567 576
256. R.T. Schermuly, S.S. Pullamsetti, G. Kwapiszewska, R. Dumitrascu, X. Tian, and N. Weissmann et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy Circulation 115 17 2007 2331 2339
257. R.T. Schermuly, J.P. Stasch, S.S. Pullamsetti, R. Middendorff, D. Muller, and K.D. Schluter et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Eur Respir J 32 4 2008 881 891
258. J.A. Schirger, H.H. Chen, M. Jougasaki, O. Lisy, G. Boerrigter, and A. Cataliotti et al. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention Circulation 109 2 2004 249 254
259. B. Seo, B.S. Oemar, R. Siebenmann, L. von Segesser, and T.F. Luscher Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels Circulation 89 3 1994 1203 1208
260. F. Seta, M. Rahmani, P.V. Turner, and C.D. Funk Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline PLoS One 6 8 2011 e23439
261. H. Shimokawa, and M. Rashid Development of Rho-kinase inhibitors for cardiovascular medicine Trends Pharmacol Sci 28 6 2007 296 302
262. K. Shinmura, K. Tamaki, T. Sato, H. Ishida, and R. Bolli Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor Am J Physiol Heart Circ Physiol 288 5 2005 H2093 H2101
263. X. Shi-Wen, Y. Chen, C.P. Denton, M. Eastwood, E.A. Renzoni, and G. Bou-Gharios et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts Mol Biol Cell 15 6 2004 2707 2719
264. N. Shukla, G. Rossoni, M. Hotston, A. Sparatore, P. Del Soldato, and V. Tazzari et al. Effect of hydrogen sulphide-donating sildenafil (ACS6) on erectile function and oxidative stress in rabbit isolated corpus cavernosum and in hypertensive rats BJU Int 103 11 2009 1522 1529
265. P.N. Sidharta, P.L. van Giersbergen, A. Halabi, and J. Dingemanse Macitentan: entry-into-humans study with a new endothelin receptor antagonist Eur J Clin Pharmacol 67 10 2011 977 984
266. G. Simonneau, I.M. Robbins, M. Beghetti, R.N. Channick, M. Delcroix, and C.P. Denton et al. Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 1 Suppl. 2009 S43 S54
267. G. Simonneau, L.J. Rubin, N. Galie, R.J. Barst, T.R. Fleming, and A.E. Frost et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 8 2008 521 530
268. G. Simonneau, A. Torbicki, M.M. Hoeper, M. Delcroix, K. Karlocai, and N. Galie et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension Eur Respir J 40 4 2012 874 880
269. G. Simonneau, L.J. Hwang, S.A. Teal, and N. Galie Incidence of subdural hematoma in patients with pulmonary arterial hypertension (PAH) in two randomized controlled clinical trials Eur Respir J 40 Suppl. 56 2012 941
270. O. Sitbon, M. Delcroix, E. Bergot, A. Boonstra, P. Escribano Subias, and N. Galiè et al. EPITOME-2: evaluation of a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from an originally approved formulation Eur Respir J 40 Suppl. 56 2012 947
271. O. Sitbon, M. Humbert, X. Jais, V. Ioos, A.M. Hamid, and S. Provencher et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 23 2005 3105 3111
272. O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, and P. Herve et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 4 2002 780 788
273. E. Soon, A.M. Holmes, C.M. Treacy, N.J. Doughty, L. Southgate, and R.D. Machado et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension Circulation 122 9 2010 920 927
274. M.D. Southall, and M.R. Vasko Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons J Biol Chem 276 19 2001 16083 16091
275. R. Souza, O. Sitbon, F. Parent, G. Simonneau, and M. Humbert Long term imatinib treatment in pulmonary arterial hypertension Thorax 61 8 2006 736
276. J.P. Stasch, P. Pacher, and O.V. Evgenov Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease Circulation 123 20 2011 2263 2273
277. R.H. Steinhorn Nitric oxide and beyond: new insights and therapies for pulmonary hypertension J Perinatol 28 Suppl. 3 2008 S67 S71
278. J. Stitham, C. Midgett, K.A. Martin, and J. Hwa Prostacyclin: an inflammatory paradox Front Pharmacol 2 2011 24
279. G. Sutendra, S. Bonnet, G. Rochefort, A. Haromy, K.D. Folmes, and G.D. Lopaschuk et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension Sci Transl Med 2 44 2010 44ra58
280. A. Szczeklik, R. Pieton, J. Sieradzki, and R. Nizankowski The effects of prostacyclin on glycemia and insulin release in man Prostaglandins 19 6 1980 959 968
281. B. Sztrymf, F. Coulet, B. Girerd, A. Yaici, X. Jais, and O. Sitbon et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation Am J Respir Crit Care Med 177 12 2008 1377 1383
282. D.M. Tabima, S. Frizzell, and M.T. Gladwin Reactive oxygen and nitrogen species in pulmonary hypertension Free Radic Biol Med 52 9 2012 1970 1986
283. H. Takahashi, N. Goto, Y. Kojima, Y. Tsuda, Y. Morio, and M. Muramatsu et al. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension Am J Physiol Lung Cell Mol Physiol 290 3 2006 L450 L458
284. M.C. Tamby, Y. Chanseaud, M. Humbert, J. Fermanian, P. Guilpain, and P. Garcia-de-la-Pena-Lefebvre et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension Thorax 60 9 2005 765 772
285. B. Tantini, A. Manes, E. Fiumana, C. Pignatti, C. Guarnieri, and R. Zannoli et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells Basic Res Cardiol 100 2 2005 131 138
286. V.F. Tapson, F. Torres, F. Kermeen, A.M. Keogh, R.P. Allen, and R.P. Frantz et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial Chest 142 6 2012 1383 1390
287. S. Tawara, Y. Fukumoto, and H. Shimokawa Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats J Cardiovasc Pharmacol 50 2 2007 195 200
288. B. Terrier, M.C. Tamby, L. Camoin, P. Guilpain, C. Broussard, and G. Bussone et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension Am J Respir Crit Care Med 177 10 2008 1128 1134
289. R.G. Tilton, C.L. Munsch, S.J. Sherwood, S.J. Chen, Y.F. Chen, and C. Wu et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist Pulm Pharmacol Ther 13 2 2000 87 97
290. T.J. Toward, N. Smith, and K.J. Broadley Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease Am J Respir Crit Care Med 169 2 2004 227 234
291. R.C. Trembath, J.R. Thomson, R.D. Machado, N.V. Morgan, C. Atkinson, and I. Winship et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia N Engl J Med 345 5 2001 325 334
292. T.K. Trow, and D.B. Taichman Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism Respir Med 103 7 2009 951 962
293. N.D. Tsihlis, C.S. Oustwani, A.K. Vavra, Q. Jiang, L.K. Keefer, and M.R. Kibbe Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10 Cell Biochem Biophys 60 1-2 2011 89 97
294. L. Tu, F.S. De Man, B. Girerd, A. Huertas, M.C. Chaumais, and F. Lecerf et al. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents Am J Respir Crit Care Med 186 7 2012 666 676
295. L. Tu, L. Dewachter, B. Gore, E. Fadel, P. Dartevelle, and G. Simonneau et al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension Am J Respir Cell Mol Biol 45 2 2011 311 322
296. R.M. Tuder, C.D. Cool, M.W. Geraci, J. Wang, S.H. Abman, and L. Wright et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension Am J Respir Crit Care Med 159 6 1999 1925 1932
297. US NIH ClinicalTrials.gov Pulmonary hypertension: assessment of cell therapy (PHACeT) 2010 (online, http://clinicaltrials.gov/ct2/show/NCT00469027? term=PHACeT&rank=1)
298. O. Uzun, O. Balbay, N.U. Comunoglu, O. Yavuz, A. Nihat Annakkaya, and S. Guler et al. Hypobaric-hypoxia-induced pulmonary damage in rats ameliorated by antioxidant erdosteine Acta Histochem 108 1 2006 59 68
299. J. Vane, and R.E. Corin Prostacyclin: a vascular mediator Eur J Vasc Endovasc Surg 26 6 2003 571 578
300. J. Venitz, J. Zack, H. Gillies, M. Allard, J. Regnault, and C. Dufton Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension J Clin Pharmacol 52 12 2011 1784 1805
301. M. Vercauteren, D. Strasser, E. Vezzali, A. Stalder, M. Iglarz, and P. Hess et al. Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists ERS 2012 P3898 (http://www.ers-education.org/ersMade/ abstract-print-12/files/402.pdf)
302. N.F. Voelkel, H.J. Bogaard, A.A. Al Husseini, L. Farkas, J. Gomez-Arroyo, and R. Natarajan Antioxidants for the treatment of patients with severe angioproliferative pulmonary hypertension? Antioxid Redox Signal 18 14 2012 1810 1817
303. N.F. Voelkel, R.M. Tuder, J. Bridges, and W.P. Arend Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline Am J Respir Cell Mol Biol 11 6 1994 664 675
304. Z. Wang, N. Jin, S. Ganguli, D.R. Swartz, L. Li, and R.A. Rhoades Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction Am J Respir Cell Mol Biol 25 5 2001 628 635
305. X.X. Wang, F.R. Zhang, Y.P. Shang, J.H. Zhu, X.D. Xie, and Q.M. Tao et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial J Am Coll Cardiol 49 14 2007 1566 1571
306. J. Wharton, N. Davie, P.D. Upton, M.H. Yacoub, J.M. Polak, and N.W. Morrell Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells Circulation 102 25 2000 3130 3136
307. J. Wharton, J.W. Strange, G.M. Moller, E.J. Growcott, X. Ren, and A.P. Franklyn et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells Am J Respir Crit Care Med 172 1 2005 105 113
308. M.R. Wilkins Selective or nonselective endothelin receptor blockade in
309. M.R. Wilkins, O. Ali, W. Bradlow, J. Wharton, A. Taegtmeyer, and C.J. Rhodes et al. Simvastatin as a Treatment for Pulmonary Hypertension Trial (SiPHT) Am J Respir Crit Care Med 181 10 2010 1106 1113
310. B.M. Wirostko, C. Tressler, L.J. Hwang, G. Burgess, and A.M. Laties Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension BMJ 344 2012 e554
311. H. Wise Multiple signalling options for prostacyclin Acta Pharmacol Sin 24 7 2003 625 630
312. L. Witchey-Lakshmanan, N. Palepu, and B.B. Teja A novel formulation of epoprostenol with antimicrobial properties, administered under ambient conditions, for treatment of patients with pulmonary arterial hypertension Am J Respir Crit Care Med 181 A3364 2010
313. P.J. Wright Comparison of phosphodiesterase type 5 (PDE5) inhibitors Int J Clin Pract 60 8 2006 967 975
314. X.Q. Xing, Y. Gan, S.J. Wu, P. Chen, R. Zhou, and X.D. Xiang Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway Med Hypotheses 68 5 2007 1108 1113
315. H. Yuki, S. Sato, Y. Arisaka, S. Kato, and H. Tomoike Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats Tohoku J Exp Med 173 4 1994 371 375
316. W.H. Zhang, C.P. Liu, Y.J. Zhang, Y.Q. Ji, W.X. Lu, and Q. Zeng Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats Scand Cardiovasc J 2012
317. Y.D. Zhao, D.W. Courtman, Y. Deng, L. Kugathasan, Q. Zhang, and D.J. Stewart Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease Circ Res 96 4 2005 442 450
318. W. Zhou, K. Hashimoto, K. Goleniewska, J.F. O'Neal, S. Ji, and T.S. Blackwell et al. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells J Immunol 178 2 2007 702 710
319. J.H. Zhu, X.X. Wang, F.R. Zhang, Y.P. Shang, Q.M. Tao, and J.Z. Chen Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study Pediatr Transplant 12 6 2008 650 655
320. B.S. Zuckerbraun, P. George, and M.T. Gladwin Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling Cardiovasc Res 89 3 2011 542 552
321. B.S. Zuckerbraun, D.A. Stoyanovsky, R. Sengupta, R.A. Shapiro, B.A. Ozanich, and J. Rao et al. Nitric oxide-induced inhibition of smooth muscle cell proliferation involves S-nitrosation and inactivation of RhoA Am J Physiol Cell Physiol 292 2 2007 C824 C831